Spinocerebellar ataxia type-13

From WikiMD's WELLNESSPEDIA

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Spinocerebellar ataxia type 13
Synonyms SCA13
Pronounce N/A
Specialty N/A
Symptoms N/A
Complications N/A
Onset Childhood or adulthood
Duration Chronic
Types N/A
Causes Genetic mutation in the KCNC3 gene
Risks Family history
Diagnosis Genetic testing, neurological examination
Differential diagnosis N/A
Prevention N/A
Treatment Symptomatic treatment, physical therapy, occupational therapy
Medication N/A
Prognosis Variable prognosis
Frequency Rare
Deaths N/A


Spinocerebellar ataxia type 13 (SCA13) is a rare, genetic condition that affects the cerebellum and causes progressive problems with movement. It is one of several types of spinocerebellar ataxia (SCA), which are all characterized by degenerative changes in the part of the brain related to the control of movement.

Symptoms[edit]

The symptoms of SCA13 can vary widely, even among members of the same family. They typically include poor coordination of movements (ataxia), difficulty with balance, and problems with speech (dysarthria). Some people may also have mild intellectual disability or learning problems.

Causes[edit]

SCA13 is caused by mutations in the KCNC3 gene. This gene provides instructions for making a protein that is involved in sending signals in nerve cells, particularly in the cerebellum. Mutations in the KCNC3 gene disrupt these signals, leading to the symptoms of SCA13.

Diagnosis[edit]

Diagnosis of SCA13 is based on the presence of characteristic neurological symptoms, a family history of the disease, and genetic testing. Genetic testing can confirm a diagnosis by identifying a mutation in the KCNC3 gene.

Treatment[edit]

There is currently no cure for SCA13. Treatment is focused on managing symptoms and may include physical therapy, speech therapy, and medications to control spasticity.

Prognosis[edit]

The prognosis for people with SCA13 varies. Some people may have mild symptoms and a normal lifespan, while others may have severe symptoms and a shortened lifespan.

See also[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.